Detailed Mechanism Funding and Narrative

Years of mechanism: 2012 2013 2014 2015 2016 2017 2018 2019 2020

Details for Mechanism ID: 14421
Country/Region: Zambia
Year: 2014
Main Partner: Southern Province Medical Office - Zambia
Main Partner Program: NA
Organizational Type: Host Country Government Agency
Funding Agency: HHS/CDC
Total Funding: $2,978,564 Additional Pipeline Funding: $1,157,381

NOTE: The following is taken from summaries released by PEPFAR on the PEPFAR Data Dashboard. They are incomplete summary paragraphs only and do not contain the full mechanism details. When the full narratives are released, we will update the mechanism pages accordingly.

The Southern Province Medical Office (SPMO) FY 2014-2015 Operational Plan (COP) covers the 13 districts in the province with a population of about 1,678,540 and annual growth rate of 2.9%.The HIV prevalence is estimated at 14.5% (DHSZ, 2007) translating 243, 388 people with HIV infection of which 97,355 people require treatment while currently 69,002 are active on treatment. The TB burden remains high with the notification rate of 341/100,000 while the HIV testing rates remain as low as 25%. The SPMO will focus on activities that will improve direct service delivery (DSD), and HIV patient outcomes, health systems capacity strengthening and foster ownership of programs at district and facility level. The goals is to significantly contribute to the reduction in maternal mortality and AIDS related deaths, and prevent new HIV infections through combination HIV prevention and treatment and community engagement. Important components addressed include retention of clients in treatment and care with a renewed focus on HIV related nutritional aspects. This COP aligns with the national development plan and strategic frameworks for meeting the MDGs related to health. In this COP, cost efficiency and effectiveness has been addressed through proposed reduction of costs with emphasis on accountability and effective models. The transitioning from high cost models to local ownership has been proposed. Integrated planning at district and facility level in cascading fashion for sustainability is promoted. More emphasis has been placed on monitoring and use of data at the point of generation with each technical area having detailed monitoring and evaluation. The budget level will change due to increase number of districts from 11 to 13.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $450,000
Care: TB/HIV (HVTB) $323,019
Care: Pediatric Care and Support (PDCS) $200,000
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $100,000
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $170,000
Testing: HIV Testing and Counseling (HVCT) $0
Sexual Prevention: Other Sexual Prevention (HVOP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $90,000
Treatment: Adult Treatment (HTXS) $1,345,545
Treatment: Pediatric Treatment (PDTX) $300,000
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
C2.1.D By Age: <15 2015 2,601
C2.1.D By Age: <15 2015 5,281
C2.1.D By Age: 15+ 2015 19,149
C2.1.D By Age: 15+ 2015 38,878
C2.1.D By Age/Sex: <15 Female 2015 1,330
C2.1.D By Age/Sex: <15 Female 2015 2,700
C2.1.D By Age/Sex: <15 Male 2015 1,271
C2.1.D By Age/Sex: <15 Male 2015 2,580
C2.1.D By Age/Sex: 15+ Female 2015 10,706
C2.1.D By Age/Sex: 15+ Female 2015 21,736
C2.1.D By Age/Sex: 15+ Male 2015 8,444
C2.1.D By Age/Sex: 15+ Male 2015 17,143
C2.1.D By Sex: Female 2015 12,171
C2.1.D By Sex: Female 2015 24,712
C2.1.D By Sex: Male 2015 9,579
C2.1.D By Sex: Male 2015 19,448
C2.1.D Number of HIV-positive individuals receiving a minimum of one clinical service 2015 21,750
C2.1.D Number of HIV-positive individuals receiving a minimum of one clinical service 2015 44,160
C2.1.D Sum of Age disaggregates 2015 21,750
C2.1.D Sum of Age disaggregates 2015 44,159
C2.1.D Sum of Age/Sex disaggregates 2015 21,751
C2.1.D Sum of Age/Sex disaggregates 2015 44,159
C2.1.D Sum of Sex disaggregates 2015 21,750
C2.1.D Sum of Sex disaggregates 2015 44,160
C2.1.D_NGI By Age: <15 2015 7,883
C2.1.D_NGI By Age: 15+ 2015 58,027
C2.1.D_NGI By Age/Sex: <15 Female 2015 4,029
C2.1.D_NGI By Age/Sex: <15 Male 2015 3,851
C2.1.D_NGI By Age/Sex: 15+ Female 2015 32,442
C2.1.D_NGI By Age/Sex: 15+ Male 2015 25,587
C2.1.D_NGI By Sex: Female 2015 36,883
C2.1.D_NGI By Sex: Male 2015 29,027
C2.1.D_NGI Number of HIV-positive individuals receiving a minimum of one clinical service 2015 65,910
C2.1.D_NGI Sum of Age disaggregates 2015 65,910
C2.1.D_NGI Sum of Age/Sex disaggregates 2015 65,909
C2.1.D_NGI Sum of Sex disaggregates 2015 65,910
C2.4.D Number of HIV-positive individuals receiving a minimum of one clinical service 2015 44,160
C2.4.D Number of HIV-positive patients who were screened for TB in HIV care or treatment setting 2015 29,776
HTS_TST Age/sex: <1 Female 2015 205
HTS_TST Age/sex: <1 Female 2015 416
HTS_TST Age/sex: <1 Female 2015 622
HTS_TST Age/sex: <1 Male 2015 179
HTS_TST Age/sex: <1 Male 2015 363
HTS_TST Age/sex: <1 Male 2015 542
HTS_TST Age/sex: 1-4 Female 2015 457
HTS_TST Age/sex: 1-4 Female 2015 929
HTS_TST Age/sex: 1-4 Female 2015 1,386
HTS_TST Age/sex: 1-4 Male 2015 381
HTS_TST Age/sex: 1-4 Male 2015 773
HTS_TST Age/sex: 1-4 Male 2015 1,154
HTS_TST Age/sex: 10-14 Female 2015 1,357
HTS_TST Age/sex: 10-14 Female 2015 2,754
HTS_TST Age/sex: 10-14 Female 2015 4,111
HTS_TST Age/sex: 10-14 Male 2015 922
HTS_TST Age/sex: 10-14 Male 2015 1,873
HTS_TST Age/sex: 10-14 Male 2015 2,795
HTS_TST Age/sex: 15-19 Female 2015 3,223
HTS_TST Age/sex: 15-19 Female 2015 6,545
HTS_TST Age/sex: 15-19 Female 2015 9,768
HTS_TST Age/sex: 15-19 Male 2015 2,321
HTS_TST Age/sex: 15-19 Male 2015 4,712
HTS_TST Age/sex: 15-19 Male 2015 7,032
HTS_TST Age/sex: 20-24 Female 2015 17,340
HTS_TST Age/sex: 20-24 Female 2015 25,881
HTS_TST Age/sex: 20-24 Female 2015 8,541
HTS_TST Age/sex: 20-24 Male 2015 6,224
HTS_TST Age/sex: 20-24 Male 2015 12,637
HTS_TST Age/sex: 20-24 Male 2015 18,862
HTS_TST Age/sex: 25-49 Female 2015 27,050
HTS_TST Age/sex: 25-49 Female 2015 40,373
HTS_TST Age/sex: 25-49 Female 2015 13,323
HTS_TST Age/sex: 25-49 Male 2015 8,897
HTS_TST Age/sex: 25-49 Male 2015 18,064
HTS_TST Age/sex: 25-49 Male 2015 26,961
HTS_TST Age/sex: 5-9 Female 2015 707
HTS_TST Age/sex: 5-9 Female 2015 1,435
HTS_TST Age/sex: 5-9 Female 2015 2,142
HTS_TST Age/sex: 5-9 Male 2015 579
HTS_TST Age/sex: 5-9 Male 2015 1,176
HTS_TST Age/sex: 5-9 Male 2015 1,755
HTS_TST Age/sex: 50+ Female 2015 4,330
HTS_TST Age/sex: 50+ Female 2015 6,463
HTS_TST Age/sex: 50+ Female 2015 2,133
HTS_TST Age/sex: 50+ Male 2015 2,069
HTS_TST Age/sex: 50+ Male 2015 4,201
HTS_TST Age/sex: 50+ Male 2015 6,270
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2015 5,553
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2015 2,735
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2015 4,138
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2015 2,038
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2015 55,342
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2015 27,258
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2015 39,565
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2015 19,487
HTS_TST Aggregated Age/sex: <15 Female 2015 8,289
HTS_TST Aggregated Age/sex: <15 Male 2015 6,177
HTS_TST Aggregated Age/sex: 15+ Female 2015 82,598
HTS_TST Aggregated Age/sex: 15+ Male 2015 59,052
HTS_TST By Test Result: Negative 2015 44,997
HTS_TST By Test Result: Negative 2015 91,357
HTS_TST By Test Result: Negative 2015 136,354
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 51,518
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 104,597
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 156,115
HTS_TST Sum of Age/Sex disaggregates 2015 104,598
HTS_TST Sum of Age/Sex disaggregates 2015 156,117
HTS_TST Sum of Age/Sex disaggregates 2015 51,518
HTS_TST Sum of Aggregated Age/Sex <15 2015 9,691
HTS_TST Sum of Aggregated Age/Sex <15 2015 14,466
HTS_TST Sum of Aggregated Age/Sex <15 2015 4,773
HTS_TST Sum of Aggregated Age/Sex 15+ 2015 94,907
HTS_TST Sum of Aggregated Age/Sex 15+ 2015 141,650
HTS_TST Sum of Aggregated Age/Sex 15+ 2015 46,745
HTS_TST Sum of Aggregated Age/Sex disaggregates 2015 104,598
HTS_TST Sum of Aggregated Age/Sex disaggregates 2015 156,116
HTS_TST Sum of Aggregated Age/Sex disaggregates 2015 51,518
HTS_TST Sum of Test Result disaggregates 2015 51,518
HTS_TST Sum of Test Result disaggregates 2015 104,598
HTS_TST Sum of Test Result disaggregates 2015 156,116
HTS_TST_POS By Test Result: Positive 2015 6,521
HTS_TST_POS By Test Result: Positive 2015 13,241
HTS_TST_POS By Test Result: Positive 2015 19,762
KP_PREV By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2015 49
KP_PREV By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2015 22
KP_PREV By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2015 22
KP_PREV By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2015 22
KP_PREV By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2015 21
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2015 115
LAB_ACC By site support type: Technical Assistance-only (TA) 2015 10
LAB_ACC Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation 2015 10
LAB_ACC Sum of Support Type disaggregates 2015 10
LAB_CAP By clinical laboratories 2015 22
LAB_CAP By Point-of-care testing sites 2015 81
LAB_CAP By site support type: Direct Service Delivery (DSD) 2015 100
LAB_CAP Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests 2015 204
LAB_CAP Sum of Site Support Type disaggregates 2015 100
PMTCT_ARV Life-long ART (including Option B+) 2015 631
PMTCT_ARV Life-long ART (including Option B+) 2015 310
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2015 639
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2015 316
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2015 631
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2015 310
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2015 240
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2015 118
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2015 391
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2015 192
PMTCT_ARV Sum of New and Current disaggregates 2015 631
PMTCT_ARV Sum of New and Current disaggregates 2015 310
PMTCT_ARV Sum of Regimen Type disaggregates 2015 631
PMTCT_ARV Sum of Regimen Type disaggregates 2015 310
PMTCT_ARV_NGI Life-long ART (including Option B+) 2015 941
PMTCT_ARV_NGI Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2015 955
PMTCT_ARV_NGI Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2015 941
PMTCT_ARV_NGI Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2015 358
PMTCT_ARV_NGI Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2015 583
PMTCT_ARV_NGI Sum of New and Current disaggregates 2015 941
PMTCT_ARV_NGI Sum of Regimen disaggregates 2015 941
PMTCT_EID By infants who received a virologic test within 2 months of birth 2015 92
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2015 188
PMTCT_EID By infants with a positive virologic test result within 12 months of birth 2015 44
PMTCT_EID Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT) 2015 1,417
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2015 261
PMTCT_EID Sum of Infant Age disaggregates 2015 280
PMTCT_SITE By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women 2015 8
PMTCT_SITE By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women 2015 37
PMTCT_SITE By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services) 2015 37
PMTCT_SITE Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women 2015 45
PMTCT_SITE Sum of Numerator Support Type disaggregates 2015 45
PMTCT_SITE Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services) 2015 45
PMTCT_SITE_den Sum of Denominator Support Type disaggregates 2015 37
PMTCT_STAT By: Known positives at entry 2015 227
PMTCT_STAT By: Known positives at entry 2015 111
PMTCT_STAT By: Number of new positives identified 2015 408
PMTCT_STAT By: Number of new positives identified 2015 201
PMTCT_STAT Number of new ANC and L&D clients 2015 3,990
PMTCT_STAT Number of new ANC and L&D clients 2015 3,990
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2015 3,990
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2015 3,990
PMTCT_STAT Sum of Positives Status disaggregates 2015 635
PMTCT_STAT Sum of Positives Status disaggregates 2015 312
PMTCT_STAT_NGI By: Known positives at entry 2015 338
PMTCT_STAT_NGI By: Number of new positives identified 2015 609
PMTCT_STAT_NGI Number of new ANC and L&D clients 2015 7,980
PMTCT_STAT_NGI Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2015 7,980
PMTCT_STAT_NGI Sum of Positives Status disaggregates 2015 947
PP_PREV Age/sex: 10-14 Female 2015 142,714
PP_PREV Age/sex: 10-14 Female 2015 44,140
PP_PREV Age/sex: 10-14 Male 2015 24,798
PP_PREV Age/sex: 10-14 Male 2015 7,670
PP_PREV Age/sex: 15-19 Female 2015 50,597
PP_PREV Age/sex: 15-19 Female 2015 15,650
PP_PREV Age/sex: 15-19 Male 2015 34,071
PP_PREV Age/sex: 15-19 Male 2015 10,540
PP_PREV Age/sex: 20-24 Female 2015 59,693
PP_PREV Age/sex: 20-24 Female 2015 18,460
PP_PREV Age/sex: 20-24 Male 2015 55,612
PP_PREV Age/sex: 20-24 Male 2015 17,200
PP_PREV Age/sex: 25-49 Female 2015 195,609
PP_PREV Age/sex: 25-49 Female 2015 60,500
PP_PREV Age/sex: 25-49 Male 2015 87,751
PP_PREV Age/sex: 25-49 Male 2015 27,140
PP_PREV Age/sex: 50+ Female 2015 38,120
PP_PREV Age/sex: 50+ Female 2015 11,790
PP_PREV Age/sex: 50+ Male 2015 37,996
PP_PREV Age/sex: 50+ Male 2015 11,750
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2015 502,128
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2015 224,840
PP_PREV Sum of Age/Sex disaggregates 2015 726,961
PP_PREV Sum of Age/Sex disaggregates 2015 224,840
PP_PREV Total number of people in the target population 2015 1,141,297
PP_PREV Total number of people in the target population 2015 352,980
QI_SITE By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months 2015 13
QI_SITE By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC 2015 15
QI_SITE By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months 2015 7
QI_SITE By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC 2015 8
QI_SITE Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months 2015 20
QI_SITE Sum of Numerator Site Support Type disaggregates 2015 20
QI_SITE Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC 2015 42
QI_SITE_den Sum of Denominator Site Support Type disaggregates 2015 23
SITE_SUPP By program area/support type: Care and Support Direct Service Delivery (DSD) 2015 39
SITE_SUPP By program area/support type: Care and Support Technical Assistance-only (TA) 2015 39
SITE_SUPP By program area/support type: General Population Prevention Direct Service Delivery (DSD) 2015 23
SITE_SUPP By program area/support type: General Population Prevention Technical Assistance-only (TA) 2015 39
SITE_SUPP By program area/support type: HTC Direct Service Delivery (DSD) 2015 39
SITE_SUPP By program area/support type: HTC Technical Assistance-only (TA) 2015 245
SITE_SUPP By program area/support type: Lab Direct Service Delivery (DSD) 2015 22
SITE_SUPP By program area/support type: Lab Technical Assistance-only (TA) 2015 76
SITE_SUPP By program area/support type: PMTCT Direct Service Delivery (DSD) 2015 8
SITE_SUPP By program area/support type: PMTCT Technical Assistance-only (TA) 2015 39
SITE_SUPP By program area/support type: TB/HIV Direct Service Delivery (DSD) 2015 39
SITE_SUPP By program area/support type: TB/HIV Technical Assistance-only (TA) 2015 233
SITE_SUPP By program area/support type: Treatment Direct Service Delivery (DSD) 2015 39
SITE_SUPP By program area/support type: Treatment Technical Assistance-only (TA) 2015 24
SITE_SUPP By program area/support type: VMMC Direct Service Delivery (DSD) 2015 24
SITE_SUPP Number of unique sites supported by PEPFAR 2015 284
TB_ARTSITE By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units 2015 64
TB_ARTSITE By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period 2015 54
TB_ARTSITE By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units 2015 32
TB_ARTSITE By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period 2015 26
TB_ARTSITE Sum of Numerator Site Support Type disaggregates 2015 80
TB_ARTSITE The number of PEPFAR-supported TB basic management units 2015 96
TB_ARTSITE The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period 2015 80
TB_ARTSITE_den Sum of Denominator Site Support Type disaggregates 2015 96
TX_CURR Age/Sex: <1 Female 2015 167
TX_CURR Age/Sex: <1 Female 2015 340
TX_CURR Age/Sex: <1 Male 2015 109
TX_CURR Age/Sex: <1 Male 2015 222
TX_CURR Age/Sex: 1-4 Female 2015 537
TX_CURR Age/Sex: 1-4 Female 2015 1,089
TX_CURR Age/Sex: 1-4 Male 2015 415
TX_CURR Age/Sex: 1-4 Male 2015 842
TX_CURR Age/Sex: 15+ Female 2015 16,799
TX_CURR Age/Sex: 15+ Female 2015 34,106
TX_CURR Age/Sex: 15+ Male 2015 11,387
TX_CURR Age/Sex: 15+ Male 2015 23,119
TX_CURR Age/Sex: 5-14 Female 2015 1,537
TX_CURR Age/Sex: 5-14 Female 2015 3,121
TX_CURR Age/Sex: 5-14 Male 2015 1,091
TX_CURR Age/Sex: 5-14 Male 2015 2,215
TX_CURR Aggregated Age/Sex: <1 Female 2015 167
TX_CURR Aggregated Age/Sex: <1 Female 2015 340
TX_CURR Aggregated Age/Sex: <1 Male 2015 109
TX_CURR Aggregated Age/Sex: <1 Male 2015 222
TX_CURR Aggregated Age/Sex: <15 Female 2015 2,241
TX_CURR Aggregated Age/Sex: <15 Female 2015 4,550
TX_CURR Aggregated Age/Sex: <15 Male 2015 1,615
TX_CURR Aggregated Age/Sex: <15 Male 2015 3,279
TX_CURR Aggregated Age/Sex: 15+ Female 2015 16,799
TX_CURR Aggregated Age/Sex: 15+ Female 2015 34,106
TX_CURR Aggregated Age/Sex: 15+ Male 2015 11,387
TX_CURR Aggregated Age/Sex: 15+ Male 2015 23,119
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2015 32,042
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2015 65,054
TX_CURR Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] 2015 1
TX_CURR Sum of age/sex disaggregates 2015 7,829
TX_CURR Sum of Age/Sex disaggregations 2015 3,856
TX_CURR Sum of Aggregated Age/Sex <15 2015 3,856
TX_CURR Sum of Aggregated Age/Sex <15 2015 7,829
TX_CURR Sum of Aggregated Age/Sex 15+ 2015 28,186
TX_CURR Sum of Aggregated Age/Sex 15+ 2015 57,225
TX_CURR Sum of Aggregated Age/Sex disaggregates 2015 32,042
TX_CURR Sum of Aggregated Age/Sex disaggregates 2015 65,054
TX_CURR_NGI Age/Sex: <1 Female 2015 507
TX_CURR_NGI Age/Sex: <1 Male 2015 331
TX_CURR_NGI Age/Sex: 1-4 Female 2015 1,626
TX_CURR_NGI Age/Sex: 1-4 Male 2015 1,256
TX_CURR_NGI Age/Sex: 15+ Female 2015 50,905
TX_CURR_NGI Age/Sex: 15+ Male 2015 34,506
TX_CURR_NGI Age/Sex: 5-14 Female 2015 4,659
TX_CURR_NGI Age/Sex: 5-14 Male 2015 3,307
TX_CURR_NGI Aggregated Age/Sex: <1 Female 2015 507
TX_CURR_NGI Aggregated Age/Sex: <1 Male 2015 331
TX_CURR_NGI Aggregated Age/Sex: <15 Female 2015 6,792
TX_CURR_NGI Aggregated Age/Sex: <15 Male 2015 4,894
TX_CURR_NGI Aggregated Age/Sex: 15+ Female 2015 50,905
TX_CURR_NGI Aggregated Age/Sex: 15+ Male 2015 34,506
TX_CURR_NGI Number of adults and children receiving antiretroviral therapy (ART) 2015 97,097
TX_CURR_NGI Sum of Age/Sex disaggregates 2015 97,097
TX_CURR_NGI Sum of Aggregated Age/Sex <15 2015 11,686
TX_CURR_NGI Sum of Aggregated Age/Sex 15+ 2015 85,411
TX_CURR_NGI Sum of Aggregated Age/Sex disaggregates 2015 97,097
TX_NEW Aggregated Grouping by Age: <1 Male 2015 114
TX_NEW Aggregated Grouping by Age/Sex: <1 Female 2015 133
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2015 1,124
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2015 847
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2015 6,021
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2015 4,586
TX_NEW Breastfeeding status 2015 63
TX_NEW By Age/Sex: <1 Female 2015 133
TX_NEW By Age/Sex: <1 Male 2015 114
TX_NEW By Age/Sex: 1-4 Female 2015 211
TX_NEW By Age/Sex: 1-4 Male 2015 154
TX_NEW By Age/Sex: 10-14 Female 2015 475
TX_NEW By Age/Sex: 10-14 Male 2015 356
TX_NEW By Age/Sex: 15-19 Female 2015 1,163
TX_NEW By Age/Sex: 15-19 Male 2015 749
TX_NEW By Age/Sex: 20-24 Female 2015 1,700
TX_NEW By Age/Sex: 20-24 Male 2015 1,296
TX_NEW By Age/Sex: 25-49 Female 2015 2,704
TX_NEW By Age/Sex: 25-49 Male 2015 2,110
TX_NEW By Age/Sex: 5-9 Female 2015 305
TX_NEW By Age/Sex: 5-9 Male 2015 223
TX_NEW By Age/Sex: 50+ Female 2015 454
TX_NEW By Age/Sex: 50+ Male 2015 431
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2015 12,578
TX_NEW Pregnancy status 2015 441
TX_NEW Sum of Age/Sex disaggregates 2015 12,578
TX_NEW Sum of Aggregated Age/Sex disaggregates 2015 12,578
TX_RET Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 1,227
TX_RET Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 13,492
TX_RET Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 3,493
TX_RET Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 4,414
TX_RET Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 14,007
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2015 2,382
TX_RET Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 4,820
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2015 2,452
TX_RET_den Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 1,827
TX_RET_den Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 14,265
TX_RET_den Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 3,266
TX_RET_den Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 460
TX_RET_den Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 499
TX_RET_den Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 12,942
TX_SITE By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation 2015 44
TX_SITE By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites 2015 56
TX_SITE By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation 2015 22
TX_SITE By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites 2015 28
TX_SITE Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation 2015 66
TX_SITE Sum of Numerator Site Support Type disaggregates 2015 66
TX_SITE Total number of PEPFAR-supported ART sites 2015 84
TX_SITE_den Sum of Denominator Site Support Type disaggregates 2015 84
VMMC_AE Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs) 2015 19
VMMC_CIRC By Age: <1 2015 308
VMMC_CIRC By Age: 1-9 2015 28
VMMC_CIRC By Age: 10-14 2015 4,341
VMMC_CIRC By Age: 10-14 2015 4,168
VMMC_CIRC By Age: 15-19 2015 6,076
VMMC_CIRC By Age: 15-19 2015 5,947
VMMC_CIRC By Age: 20-24 2015 4,723
VMMC_CIRC By Age: 20-24 2015 4,412
VMMC_CIRC By Age: 25-49 2015 4,447
VMMC_CIRC By Age: 25-49 2015 4,397
VMMC_CIRC By Age: 50+ 2015 540
VMMC_CIRC By Age: 50+ 2015 430
VMMC_CIRC By circumcision technique: Surgical VMMC 2015 20,127
VMMC_CIRC By circumcision technique: Surgical VMMC 2015 19,686
VMMC_CIRC By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery 2015 15
VMMC_CIRC By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery 2015 21
VMMC_CIRC By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery 2015 19,409
VMMC_CIRC By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery 2015 19,665
VMMC_CIRC By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site 2015 161
VMMC_CIRC By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site 2015 460
VMMC_CIRC By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program) 2015 17,639
VMMC_CIRC By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program) 2015 18,940
VMMC_CIRC By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site) 2015 301
VMMC_CIRC By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site) 2015 286
VMMC_CIRC Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2015 20,127
VMMC_CIRC Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2015 19,686
VMMC_CIRC Sum of age disaggregates 2015 19,690
VMMC_CIRC Sum of Age disaggregations 2015 20,127
VMMC_CIRC_NGI By Age: <1 2015 308
VMMC_CIRC_NGI By Age: 1-9 2015 28
VMMC_CIRC_NGI By Age: 10-14 2015 4,168
VMMC_CIRC_NGI By Age: 15-19 2015 5,947
VMMC_CIRC_NGI By Age: 20-24 2015 4,412
VMMC_CIRC_NGI By Age: 25-49 2015 4,397
VMMC_CIRC_NGI By Age: 50+ 2015 430
VMMC_CIRC_NGI By circumcision technique: Surgical VMMC 2015 19,690
VMMC_CIRC_NGI By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery 2015 25
VMMC_CIRC_NGI By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery 2015 19,665
VMMC_CIRC_NGI By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site 2015 460
VMMC_CIRC_NGI By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program) 2015 18,940
VMMC_CIRC_NGI By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site) 2015 286
VMMC_CIRC_NGI Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2015 19,686
VMMC_CIRC_NGI Sum of Age disaggregates 2015 19,690
Cross Cutting Budget Categories and Known Amounts Total: $727,778
Renovation $150,000
Motor Vehicles: Purchased $577,778
Key Issues Identified in Mechanism
enumerations.Malaria (PMI)
Child Survival Activities
Mobile Populations
Safe Motherhood
Tuberculosis
Workplace Programs
Family Planning